Medical bottles and a syringe are seen with the Novo Nordisk brand displayed on a display within the background.
Nurphoto | Nurphoto | Getty Pictures
Danish pharmaceutical large Novo Nordisk on Tuesday cuts its full-year gross sales and revenue steerage, citing weaker progress expectations for its Wegovy weight problems drug in the important thing U.S. market.
Shares have been down 15% at 12:11 p.m. London time, shortly after the announcement (7:12 a.m. ET).
The corporate stated the decrease outlook was pushed by weaker second-half U.S. gross sales progress forecasts for its Wegovy weight reduction drug and Ozempic diabetes remedy.
“For Wegovy within the US, the gross sales outlook displays the persistent use of compounded GLP-1s, slower-than-expected market enlargement and competitors,” it added in a press release.
This can be a creating story. Please examine again for updates.
Keep forward of the curve with NextBusiness 24. Discover extra tales, subscribe to our publication, and be a part of our rising group at nextbusiness24.com